Study Of Efficacy Of Entecavir Plus Plasma Exchange For The Patients With HBV-related Acute-on-chronic Liver Failure

ObjectiveTo investigate the efficacy of the treatment with entecavir plus plasma exchange in patients with severe HBV-related acute-on-chronic liver failure.Methods76patients with HBV-related acute-on-chronic liver failure were eneolled and devided into treatment group and control group randomised. Treatment group(38patients):medical comprehensive treatment and entecavir plus plasma exchange; Control group(38patients):medical comprehensive treatment and entecavir without plasma exchange. We compared the survival rate of these two groups.ResultsThe three-month,six-month,one-year survival rate of treatment group was78.9%,76.3%,1.1%, and it was55.3%,52.6%,47.4in control group, which has significant difference (chip-square=5.036, P=0.025). The three-month. six-month, one-year survival rate in patients with early-middle stage of HBV-related acute-on-chronic liver failure in treatment group was81.8%.78.8%,75.7%, while in control group was60.6%,57.6%,51.2%, which also has significant difference (chip-square=4.230,p=0.041). However, there were not significant differences of the one-year survival rate in the patients with the final stage of HBV-related acute-on-chronic liver failure in the two groups (P>0.05).ConclusionThe results in this study support that medical comprehensive treatment with entecavir plus plasma exchange may improve the one-year survival rate of the patientswith HBV-related acute-on-chronic liver failure, especially in the early-middle stage of HBV-related acute-on-chronic liver failure.